Search results
Results from the WOW.Com Content Network
Facioscapulohumeral muscular dystrophy (FSHD) is a type of muscular dystrophy, a group of heritable diseases that cause degeneration of muscle and progressive weakness. Per the name, FSHD tends to sequentially weaken the muscles of the face, those that position the scapula, and those overlying the humerus bone of the upper arm.
Beevor’s sign is characteristic of spinal cord injury between T9 and T10 levels. [3] The sign has also been observed in amyotrophic lateral sclerosis, a disease causing progressive weakening of the muscles of multiple areas of the body, and in facioscapulohumeral muscular dystrophy (FSHD), a disease named after areas of the body it preferentially weakens (face, shoulder, and upper arm).
Reachable workspace is an outcome measure used in medicine to track disease progression in neuromuscular disorders that affect the upper extremities. [1] [2] It is defined as the space, relative to the torso, that an individual can reach by moving their upper extremities. [1]
Sunil Pradhan (born 25 June 1957) is an Indian neurologist, medical researcher and writer, known for the invention of two electrophysiological techniques. He has also described five medical signs, of which one related to Duchenne muscular dystrophy is known as Pradhan Sign, [1] [2] and the others associated with facioscapulohumeral muscular dystrophy (FSHD) and similar neuro diseases. [3]
Founded in 1950 by Paul Cohen, who lived with Facioscapulohumeral muscular dystrophy (FSHD), MDA accelerates research, advances care, and works to empower families to live longer and more independent lives [5] [6] but is perhaps known for its working relationship with comedian, entertainer and actor Jerry Lewis, its national chairman of 55 ...
Some patient portal applications enable patients to register and complete forms online, which can streamline visits to clinics and hospitals. Many portal applications also enable patients to request prescription refills online, order eyeglasses and contact lenses, access medical records, pay bills, review lab results, and schedule medical ...
Losmapimod (GW856553X) is an investigational drug that reached stage III clinical trials for multiple medical conditions, but did not prove efficacy. It was most recently in development by Fulcrum Therapeutics for the treatment of facioscapulohumeral muscular dystrophy (FSHD).
Depending on the type, muscular dystrophy can affect the patient's heart and lungs, and/or their ability to move, walk, and perform daily activities. The most common types include: Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD) Myotonic dystrophy; Limb-Girdle (LGMD) Facioscapulohumeral dystrophy (FSHD) Congenital ...